Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?

European Journal of Heart Failure

Volumn 20, Issue 4, 2018, Pages 627-629

  Packer, Milton ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; CYCLIC AMP DEPENDENT POSITIVE INOTROPIC DRUG; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INOTROPIC AGENT; LIRAGLUTIDE; PHOSPHODIESTERASE III INHIBITOR; PLACEBO; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; GLUCAGON LIKE PEPTIDE 1;

ARTICLE; BETA ADRENERGIC STIMULATION; CARDIAC MUSCLE CELL; CARDIOTOXICITY; CARDIOVASCULAR RISK; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DEVELOPMENT; DRUG SAFETY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING PRESSURE; HEART MUSCLE CONTRACTILITY; HEART RATE; HEART VENTRICLE REMODELING; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SODIUM URINE LEVEL; TREATMENT DURATION; VASODILATATION; ANALOGS AND DERIVATIVES; DRUG EFFECT; HEART CONTRACTION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

CARDIOTONIC AGENTS; CYCLIC AMP; GLUCAGON-LIKE PEPTIDE 1; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC;

EID: 85032732608     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.1047     Document Type: Article

References (15)

1. Feldman MD, Copelas L, Gwathmey JK, Phillips P, Warren SE, Schoen FJ, Grossman W, Morgan JP. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987;75:331–339.
2. Chatterjee K, De Marco T. Role of nonglycosidic inotropic agents: indications, ethics, and limitations. Med Clin North Am 2003;87:391–418.
3. Perera RK, Nikolaev VO. Compartmentation of cAMP signalling in cardiomyocytes in health and disease. Acta Physiol (Oxf) 2013;207:650–662.
4. Aoyama M, Kawase H, Bando YK, Monji A, Murohara T. Dipeptidyl peptidase 4 inhibition alleviates shortage of circulating glucagon-like peptide-1 in heart failure and mitigates myocardial remodeling and apoptosis via the exchange protein directly activated by cyclic AMP 1/ras-related protein 1 axis. Circ Heart Fail 2016;9:e002081.
5. Du J, Zhang L, Wang Z, Yano N, Zhao YT, Wei L, Dubielecka-Szczerba P, Liu PY, Zhuang S, Qin G, Zhao TC. Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts. Am J Physiol Cell Physiol 2016;310:C270–C283.
6. Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2017;2:1025–1029.
7. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–322.
8. Chaudhuri A, Ghanim H, Makdissi A, Green K, Abuaysheh S, Batra M, D Kuhadiya N, Dandona P. Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators. Diabetes Obes Metab 2017;19:729–733.
9. Nathanson D, Ullman B, Löfström U, Hedman A, Frick M, Sjöholm A, Nyström T. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 2012;55:926–935.
10. Lorenz M, Lawson F, Owens D, Raccah D, Roy-Duval C, Lehmann A, Perfetti R, Blonde L. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol 2017;16:6.
11. Hamill V, Ford I, Fox K, Böhm M, Borer JS, Ferrari R, Komajda M, Steg PG, Tavazzi L, Tendera M, Swedberg K. Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction. Am J Med 2015;128:1102–1108.
12. Wallner M, Kolesnik E, Ablasser K, Khafaga M, Wakula P, Ljubojevic S, Thon-Gutschi EM, Sourij H, Kapl M, Edmunds NJ, Kuzmiski JB, Griffith DA, Knez I, Pieske B, von Lewinski D. Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. J Mol Cell Cardiol 2015;89(Pt B):365–375.
13. 2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic beta-cells. J Biol Chem 2002;277:48146–48151.
14. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, Nilsson B, Møller JE, Hjort J, Rasmussen J, Boesgaard TW, Schou M, Videbaek L, Gustafsson I, Flyvbjerg A, Wiggers H, Tarnow L. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19:69–77.
15. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP; NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500–508.